Algorithm for Drug Causality for Epidermal Necrolysis scoring was discordant for 28 cases, clearing 43 drugs labeled as allergens

Laser well tolerated with durable posttreatment improvement through 26 weeks across skin types

In this poster presented at the 2023 Fall Clinical Dermatology Conference for PAs & NPs in Orlando, Piliang and colleagues evaluate scalp, eyebrow, and...

In this poster presented at the 2023 Fall Clinical Dermatology Conference for PAs & NPs in Orlando, Senna and colleagues analyze eyebrow and eyelash...

In this poster presented at the 2023 Fall Clinical Dermatology Conference for PAs & NPs in Orlando, Hyams and colleagues explore use of the...

In this poster presented at the 2023 Fall Clinical Dermatology Conference for PAs & NPs in Orlando, Maurer and colleagues present data from a...

71.6 percent of 712 populated zip codes with dermatologists have fewer than four dermatologists per 100,000

Organ transplant recipients have increased prevalence of poorly versus well-differentiated SCCs, and of tumors >20 mm versus ≤20 mm

Systemic responses seen across patient groups, but more complete skin clearance seen with short disease duration

Findings seen among pediatric patients aged 12 to 17 years

Unapproved products are unlikely to actually have the impact they claim and may cause bad reactions

Mean quality-of-life symptoms favor spironolactone at 12 and 24 weeks; more participants report acne improvement with spironolactone

Higher rates of exacerbation after COVID-19 vaccination seen for patients with psoriasis and low vitamin D levels

Researchers find 15-year relative survival to be 112.4 percent and all-cause standardized mortality ratio to be 0.68

U.S. cases are still at less than three per day, with 32 infections diagnosed in May so far

While absolute risk difference is small, higher risk seen for both deep vein thrombosis and pulmonary embolism

Review finds no clinically or statistically significant difference in rates of achieving PASI-75 or adverse events for biosimilars, originator biologics

No increase seen in skin cancer, nonmelanoma skin cancer, cutaneous melanoma for those treated with UVB phototherapy

Improvement seen in Skindex-16 quality-of-life scores in symptoms, emotions, functioning domains at week 8 with tirbanibulin

Average serum calcidiol 33.8 ± 15.8 ng/mL seen in patients with melasma versus 36.8 ± 15.8 ng/mL in other dermatology patients

Significantly fewer lesions receiving microdosed clindamycin, flucloxacillin required postoperative systemic antibiotics

Two-dose series offers better protection, with vaccine effectiveness of 66.0 percent compared with 35.8 percent for one-dose

Clinician Erythema Assessment success rate significantly higher after oxymetazoline treatment versus vehicle